Treatment of Connective Tissue Disease-Related Intractable Disease with Biological Therapeutics.
Treatment of Connective Tissue Disease-Related Intractable Disease with Biological Therapeutics.
复制标题
DOI：
10.2147/oarrr.s328211
复制
发表时间：
2021
期刊：
影响因子：
--
通讯作者：
Nomura S
中科院分区：
文献类型：
--
作者：
Ozaki Y;Nomura S
结缔组织病（CTD）和CTD相关难治性疾病（CTD-ID）的治疗目前依赖于类固醇治疗的使用。自2003年英夫利西单抗被批准用于类风湿关节炎以来，已经过去了大约20年。从那时起，几种生物疗法已经上市，并适用于除类风湿性关节炎以外的许多CTD和CTD-ID。虽然这些疾病患者的常规治疗很少使用，因为他们的预后差，这些情况下可能会受益于生物疗法。然而，选择生物治疗剂是困难的，因为它们与常规治疗剂相比具有不同的靶分子。本文就白塞病、银屑病关节炎、强直性脊柱炎、抗中性粒细胞胞浆抗体相关性关节炎、成人斯蒂尔病等CTD-ID的生物治疗现状以及临床应用中生物治疗的选择作一综述。
The treatment of connective tissue disease (CTD) and CTD-related intractable diseases (CTD-IDs) currently depends on the use of steroid therapy. Approximately 20 years have passed since the approval of infliximab for rheumatoid arthritis in 2003. Since then, several biological therapeutics have been marketed and adapted for many CTDs and CTD-IDs other than rheumatoid arthritis. Although conventional treatment for patients with these diseases is rarely used because of their poor prognosis, these cases may benefit from biological therapeutics. However, choosing biological therapeutics is difficult because they have different target molecules compared with conventional therapeutics. In this review, we address the current situation of biological therapeutics for CTD-IDs including Behcet’s disease, psoriatic arthritis, ankylosing spondylitis, anti-neutrophil cytoplasmic antibody-related arthritis, and adult Still’s disease, as well as the choice of biological therapeutics in clinical practice.